145 related articles for article (PubMed ID: 38490676)
21. Safety of urate-lowering therapies: managing the risks to gain the benefits.
Keenan RT
Rheum Dis Clin North Am; 2012 Nov; 38(4):663-80. PubMed ID: 23137576
[TBL] [Abstract][Full Text] [Related]
22. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
Keith MP; Gilliland WR
Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
[TBL] [Abstract][Full Text] [Related]
23. Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid levels.
Beutler AM; Rull M; Schlesinger N; Baker DG; Hoffman BI; Schumacher HR
Clin Exp Rheumatol; 2001; 19(5):595. PubMed ID: 11579724
[No Abstract] [Full Text] [Related]
24. Uricase and other novel agents for the management of patients with treatment-failure gout.
Sundy JS; Hershfield MS
Curr Rheumatol Rep; 2007 Jun; 9(3):258-64. PubMed ID: 17531181
[TBL] [Abstract][Full Text] [Related]
25. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
[TBL] [Abstract][Full Text] [Related]
26. How should we treat tophaceous gout in patients with allopurinol hypersensitivity?
Grahame R; Simmonds HA; McBride MB; Marsh FP
Adv Exp Med Biol; 1998; 431():19-23. PubMed ID: 9598024
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
[TBL] [Abstract][Full Text] [Related]
28. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.
Gandhi PK; Gentry WM; Ma Q; Bottorff MB
J Manag Care Spec Pharm; 2015 Feb; 21(2):165-75. PubMed ID: 25615006
[TBL] [Abstract][Full Text] [Related]
30. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
31. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
32. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
Stamp LK; O'Donnell JL; Zhang M; James J; Frampton C; Barclay ML; Chapman PT
Arthritis Rheum; 2011 Feb; 63(2):412-21. PubMed ID: 21279998
[TBL] [Abstract][Full Text] [Related]
33. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
[TBL] [Abstract][Full Text] [Related]
34. Predicting allopurinol response in patients with gout.
Wright DF; Duffull SB; Merriman TR; Dalbeth N; Barclay ML; Stamp LK
Br J Clin Pharmacol; 2016 Feb; 81(2):277-89. PubMed ID: 26451524
[TBL] [Abstract][Full Text] [Related]
35. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
Hosoya T; Sasaki T; Ohashi T
Clin Rheumatol; 2017 Mar; 36(3):649-656. PubMed ID: 27832384
[TBL] [Abstract][Full Text] [Related]
36. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Becker MA; MacDonald PA; Hunt B; Gunawardhana L
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1011-7. PubMed ID: 22132950
[TBL] [Abstract][Full Text] [Related]
37. Treatment failure gout: failure to treat?
Perry ME; Madhok R
Rheumatology (Oxford); 2010 Dec; 49(12):2233-4. PubMed ID: 20463191
[No Abstract] [Full Text] [Related]
38. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
[TBL] [Abstract][Full Text] [Related]
39. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
Hill EM; Sky K; Sit M; Collamer A; Higgs J
J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
[TBL] [Abstract][Full Text] [Related]
40. Allopurinol: insights from studies of dose-response relationships.
Day RO; Kannangara DR; Stocker SL; Carland JE; Williams KM; Graham GG
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):449-462. PubMed ID: 27927043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
